Robert J. Kelley - Oct 2, 2021 Form 4 Insider Report for Talis Biomedical Corp (TLIS)

Role
Chief Commercial Officer
Signature
/s/ Karen E. Flick, Attorney-in-Fact for Robert J. Kelley
Stock symbol
TLIS
Transactions as of
Oct 2, 2021
Transactions value $
$0
Form type
4
Date filed
10/5/2021, 04:48 PM
Next filing
Dec 9, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TLIS Stock Option (right to buy) Award +130K +43.74% 427K Oct 2, 2021 Common Stock 130K $6.17 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this option shall vest on the first annual anniversary of the vesting commencement date and 1/48th of the shares underlying this option shall vest monthly thereafter over 36 months.
F2 Price not required on initial report of stock option granted.